The European Commission recently approved two new indications for ramucirumab (Cyramza), which blocks the formation of new blood vessels (angiogenesis) to malignancies.

Firstly, ramucirumab is now indicated in combination with docetaxel for adults with locally advanced or metastatic nonsmall cell lung cancer that progressed after platinumbased chemotherapy.

Secondly, ramucirumab, which blocks vascular endothelial growth factor, is now approved combined with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) for metastatic colorectal cancer that progresses on or after bevacizumab, oxaliplatin and a fluoropyrimidine.